Cellectar Biosciences stock soars on FDA breakthrough designation By Investing.com
Cellectar Biosciences stock soars on FDA breakthrough designation…
5,040$
5,44%
Echtzeit-Aktienkurs CELLECTAR NEW22 DL-00001
Bid:
Ask:
Nachrichten zur CELLECTAR NEW22 DL-00001 Aktie
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy…
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
…
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
FLORHAM PARK, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…
Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript
…
UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…
Cellectar Biosciences: Still Working On That Hit (Maintain Buy)
…
Earnings call: Cellectar Biosciences outlines robust WM market strategy By Investing.com
Earnings call: Cellectar Biosciences outlines robust WM market strategy…
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
…
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…